Celularity Inc., a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey.
Research context
Celularity Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Financial Services
- Industry
- Shell Companies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
GX Acquisition Corp is currently in a long term downtrend where the price is trading 1.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 0.0.
GX Acquisition Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 558.7% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 8.3% to $-242K since the same quarter in the previous year.
Based on the above factors, GX Acquisition Corp gets an overall score of 1/5.